Enterprise Value
18.43B
Cash
2.439B
Avg Qtr Burn
N/A
Short % of Float
2.23%
Insider Ownership
0.41%
Institutional Own.
95.03%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AMVUTTRA (Vutrisiran) Details Transthyretin amyloidosis | Approved Update | |
Leqvio® (inclisiran) Details Transthyretin amyloidosis, Atherosclerotic cardiovascular disease | Approved Quarterly sales | |
OXLUMO® (lumasiran) Details Primary hyperoxaluria | Approved Quarterly sales | |
ONPATTRO® (Patisiran) Details Transthyretin amyloidosis | sNDA FDA meeting | |
FITUSIRAN Details Hemophilia | NDA Submission | |
AMVUTTRA (Vutrisiran) Details Transthyretin amyloidosis, Cardiomyopathy | Phase 3 Data readout | |
ALN-TTRsc04 Details Transthyretin amyloidosis | Phase 3 Initiation | |
ALN-HBV02 (VIR-2218) +/- VIR3434 Details Hepatitis D, Hepatitis B | Phase 2 Data readout | |
Zilebesiran (ALN-AGT) Details Metabolic disorder, Pulmonary arterial hypertension | Phase 2 Update | |
ALN-HSD Details Non-alcoholic steatohepatitis | Phase 1 Data readout | |
ALN-APP Details Alzheimer's disease, Cerebral Amyloid Angiopathy | Phase 1 Data readout | |
ALN-PNP Details Non-alcoholic steatohepatitis | Phase 1 Update | |
ALN-KHK Details Type 2 diabetes | Phase 1a Data readout | |
ALN-XDH Details Arthritis, Chronic refractory gout | Failed Discontinued | |
OXLUMO® (lumasiran) Details Kidney disease | Failed Discontinued |